Individuals and teams invited to help American College of Rheumatology develop new clinical practice guidelines for RA care
Search results for: Biologics
ACR Winter Rheumatology Symposium: Answers to Your Tough Questions about Rheumatic Disease Therapy
Panelists discuss vaccination, biologics and infection, methotrexate, cardiovascular risk, and serial immunoglobulin testing and imaging
ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise
Toxicity and appropriate targeting are challenges for small molecule researchers
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
How Rheumatologists Can Win Support and Influence Congress
Ways to use the ACR’s advocacy toolkit to contact Congressional representatives and articulate your message to lawmakers
Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis
A combination therapy with glucocorticoids may be the gold standard for treating patients with rheumatoid arthritis (RA)
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
Rheumatology Chooses Wisely
ACR identifies five practices, therapies, or procedures physicians and patients should question
Panel Addresses Drug Safety Issues in Rheumatology Products
Black box warnings, TNF inhibitors, and tofacitinib discussed
ACR Leaders Converge on Capitol Hill
American College of Rheumatology (ACR) members to discuss legislation and regulatory issues facing rheumatologists at this year’s annual ACR Advocacy Leadership Conference in Washington, D.C.
- « Previous Page
- 1
- …
- 59
- 60
- 61
- 62
- 63
- …
- 70
- Next Page »